Coronary Artery Bypass Grafts Device segmentation by type categorises four principal graft families: autologous saphenous vein grafts, arterial grafts (primarily internal mammary and radial arteries), synthetic polymer grafts, and hybrid composite grafts. Autologous vein grafts remain the most widely deployed, contributing approximately 55 % of device volume because of their availability, ease of harvest, and proven long‑term patency in low‑risk lesions. Arterial grafts, accounting for roughly 30 % of the market, are favoured in high‑risk or multi‑vessel disease owing to superior endothelial function and durability, especially the left internal mammary artery which dominates left‑descending artery bypasses. Synthetic polymer grafts hold a modest 10 % share, limited to cases where autologous material is unsuitable or when rapid deployment is required; advances in biocompatible polymers are gradually expanding this niche. Hybrid composite grafts, integrating biological and synthetic layers, represent an emerging 5 % segment driven by demand for off‑the‑shelf solutions that reduce operative time. Together, these type categories delineate the market’s structural composition, with the predominance of autologous and arterial grafts underpinning the bulk of revenue while synthetic and hybrid innovations introduce incremental growth vectors.
